<DOC>
	<DOCNO>NCT02332798</DOCNO>
	<brief_summary>This study aim assess safety , tolerability pharmacokinetics PF-04958242 multiple ascending dos subject stable schizophrenia .</brief_summary>
	<brief_title>Multiple Ascending Doses PF-04958242 Subjects With Stable Schizophrenia</brief_title>
	<detailed_description>This study aim assess safety , tolerability pharmacokinetics PF-04958242 compare placebo 14 day twice day dose multiple ascend dos subject stable schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Psychiatrically stable ( ≥3 month ) male female subject schizophrenia nonchildbearing potential age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 55 kg ( 121 lb ) . DSMIV Diagnosis Schizophrenia ; stable medication treatment regimen ≥2 month . Suicide attempt within 3 month prior screen . History risk seizure ; head injury long term abnormal result condition , abnormal EEG , clinically significant additional disease condition , current medication significant risk seizure , currently receive antipsychotic medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Multiple ascending dos</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>cognitive impairment associate schizophrenia ( CIAS )</keyword>
</DOC>